Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BCR::ABL1 status confers therapeutic sensitivity to Imatinib in patients with Chronic Myelogenous Leukemia.
The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.